Clinical trials: High Blood Sugar
Type 2 Diabetes Mellitus
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction.
- Trial name
- NCT03090464
- Testing
- Use of digital disease management tool
- Where
- 46 sites in United States
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Cholesterol; Lipidosis, Arterial Hypertension
Assessment of Lifestyle, Blood Pressure, Cholesterol and Glycated Hemoglobin in a Specific Population
The project Shall we get to know your health better? Lifestyle assessment, blood pressure and cholesterol in the population of Libbs Farmacêutica employeesLTDA.; consists of a study that will bring knowledge and enable…
- Conditions
- Cholesterol; Lipidosis, Arterial Hypertension, Blood Glucose, High
- Trial name
- LB1901 (NCT04373863)
- Where
- Brazil
- Volunteers
- 2,472 people, healthy volunteers welcome
- Sponsor
- Libbs Farmacêutica LTDA
Hyperglycaemia (Diabetic), Healthy Volunteers
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride
This is a phase 1 randomized,double-blind,placebo-controlled study with single oral dose of globalagliatin hydrochloride (SY-004) administered to chinese healthy subjects to evaluated the safety, tolerability, pharmacokinetics…
- Trial name
- NCT03171623
- Testing
- globalagliatin hydrochloride
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Yabao Pharmaceutical Group
Prediabetic State
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels…
- Trial name
- NCT00237250
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Novartis
Impaired Glucose Tolerance
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
- Trial name
- NCT01468376
- Testing
- GLU-01, GLU-02, GLU-03
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Diabetes Mellitus, Type II
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
The purposes of this study are to: Evaluate the safety and tolerability of the study drug. Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get…
- Trial name
- NCT06498284
- Testing
- HM-002-1005
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua Medicine Limited
Low Glycemic Index (GI) Food, Pre Diabetes
Determination of the Glycemic Index Values of 10 Cereal-based Products
To determine the Glycemic index values for 10 cereal-based products
- Conditions
- Low Glycemic Index (GI) Food, Pre Diabetes, Diabetes
- Trial name
- NCT06710743
- Testing
- Glucose solution Day 1, Day 8, and Day 15, Food (cereal). Ten different cereals served once each
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Diabetes Mellitus
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT00653185
- Testing
- SYR-472
- Where
- 87 sites in United States, Chile and 10 more
- Volunteers
- 369 people
- Sponsor
- Takeda
Diabetes, Pre-diabetes
Glucose Risk Assessment in Employer Populations
This is an observational study to understand the glucose characteristics of the general population (normal glucose, pre-diabetes, and diabetes).
- Conditions
- Diabetes, Pre-diabetes, Glucose Intolerance
- Trial name
- NCT04529824
- Testing
- Dexcom G6 Continuous Glucose Monitor (CGM) System
- Where
- United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- DexCom, Inc.
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Pre-diabetes, Undiagnosed Diseases
A Pivotal Clinical Investigation Confirming the Safety and Accuracy of the Glyconics-DS in Assessment of Glycated Nail Keratin in Individuals With Unknown Diabetes Status and Performance Evaluation of the Glyconics SW Package
The main clinical study objective is to confirm the accuracy of the Glyconics-DS spectrometer when used in its intended medical purpose population, i.e., in individuals with unknown diabetes risk.
- Trial name
- ANODE03 (NCT06261944)
- Testing
- Near-infrared (NIR)
- Where
- Spain
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Glyconics Ltd
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in participants with type 1 diabetes who are using an insulin pump and have high blood sugar after eating.
- Trial name
- NCT04276207
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Pre Diabetic
A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome
This study aims to investigate the effect of a cobiotic formulation, prepared as a smoothie beverage, on the ratio of intestinal microbiota of the Bacteroidetes phylum to those of the Firmicutes phylum in the stool as well as the…
- Trial name
- NCT01724736
- Testing
- NM504:
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NuMe Health
Hyperglycemias, Prediabetes
Efficacy of the pA1c®HI Postbiotic in Metabolic Regulation in Healthy Individuals With Hyperglycemia
This study will evaluate the effects of pA1c®HI, a heat-inactivated postbiotic derived from the bacterium Pediococcus acidilactici, on blood glucose regulation and other aspects of metabolic health in adults with elevated blood…
- Trial name
- CR2027 (NCT07903870)
- Testing
- Postbiotic
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Genbioma Aplicaciones SL
Postprandial Hyperglycemia
Comparison of the Postprandial Glycemic and Insulinemic Response After a Fibersym Containing Cookie With a Control
Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43.
- Trial name
- NCT04820322
- Testing
- Fibersym, Control cookie
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MGP Ingredients, Inc.
Respiratory Disorder, Cardiovascular Diseases
Study of RE.DOCTOR Vitals® Software Accuracy
The purpose of this observational trial is to advance digital health monitoring through the analysis of Photoplethysmography (PPG) waveforms collected via RE.DOCTOR Vitals software.
- Conditions
- Respiratory Disorder, Cardiovascular Diseases, Diabetes, Pre-Diabetes
- Trial name
- RE-VITAL (NCT06237322)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- RE.DOCTOR LLC
Hyperglycemia, Diabetes Mellitus
Lantus in Prediabetes
To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).
- Trial name
- NCT00348972
- Testing
- Lantus® (insulin glargine)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Impaired Glucose Tolerance (IGT)
Postmarketing Clinical Study on AO-128
The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose) 0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to diet therapy and exercise therapy, and…
- Trial name
- NCT02287402
- Testing
- AO-128
- Volunteers
- 197 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi